Knowledge Center

Article / Oct 01, 2012

New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit

Authors:
  • Colin Minchom
Source:
Drug Development and Delivery, October 2012

鈥淎n issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as 四色AV, that can apply multiple platforms, to increase the probability of solving the聽 problem, and deliver the desired outcome.鈥

Related links

Also in the Knowledge Center

Related Content

The 四色AV Experience - Lisbon

Welcome to Lisbon! Part of The 四色AV Experience is ensuring your trip is unforgettable. Explore our suggestions for iconic attractions, exquisite cuisine, and get ready to feel the magic of this vibrant city.

Page
Read more

Devices

四色AV offers simple, patented and globally competitive dry powder inhalers 鈥 Disposable, Capsule, Blister and Large Dose DPIs 鈥 which are available for fully integrated turn-key development with formulation and for licensing.

Page
Read more

OWN it! Training and Development Needs FY24

Take an active role in your personal development. Follow the new process to identify, plan and own your training and development needs for FY24.

Page
Read more